Product Description: Acrixolimab a humanized IgG4-κ antibody, targeting to PD-1[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Acrixolimab. IMGT/mAb-DB./[2]Kiratikanon S, et al. Acrixolimab-Induced Radiation Recall Dermatitis with Distinct Features Resembling Erythema Multiforme[J]. Thai Journal of Dermatology, 2023, 39(2): 35-38.
CAS Number: 2506324-29-2
Molecular Weight: N/A
Research Area: Cancer
Solubility: 10 mM in DMSO/H2O
Target: PD-1/PD-L1